Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 8/20 | 0.68 |
| ▸ | SLC6A4 | P31645 | 8/20 | 0.68 |
| ▸ | SLC6A3 | Q01959 | 8/20 | 0.68 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.68 |
| ▸ | DRD2 | P14416 | 1/20 | 0.57 |
| ▸ | DRD3 | P35462 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10819294 | 1.00 | SLC6A2 (0.68) | SLC6A2SLC6A4SLC6A3KCNH2DRD2 | |
| SCHEMBL4557697 | 1.00 | SLC6A2 (0.68) | SLC6A2SLC6A4SLC6A3KCNH2DRD2 | |
| SCHEMBL4761442 | 1.00 | SLC6A2 (0.68) | SLC6A2SLC6A4SLC6A3KCNH2DRD2 | |
| SCHEMBL14520924 | 1.00 | SLC6A2 (0.68) | SLC6A2SLC6A4SLC6A3KCNH2DRD2 | |
| SCHEMBL14520923 | 1.00 | SLC6A2 (0.68) | SLC6A2SLC6A4SLC6A3KCNH2DRD2 | |
| Hydrochloric Acid SCHEMBL4326374 | 0.98 | SLC6A2 (0.66) | SLC6A2SLC6A4SLC6A3KCNH2DRD2 | |
| SCHEMBL4713453 | 0.89 | SLC6A2 (0.65) | SLC6A2SLC6A4SLC6A3KCNH2DRD2 | |
| Hexane SCHEMBL4713252 | 0.88 | SLC6A2 (0.59) | SLC6A2SLC6A4SLC6A3KCNH2DRD2 | |
| SCHEMBL30272567 | 0.86 | SLC6A2 (0.63) | SLC6A2SLC6A4SLC6A3KCNH2DRD2 | |
| SCHEMBL11083508 | 0.85 | SLC6A2 (0.59) | SLC6A2SLC6A4SLC6A3KCNH2DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2007751-B1 | AZABICYCLO [3. 1. O] HEXYL DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | GLAXO GROUP LTD (GB) | 2013-08-21 | — | — | EP | disclosed |
| US-8263782-B2 | Azabicyclo (3.1.0) hexane derivatives useful as modulators of dopamine D3 receptors | GLAXO GROUP LIMITED (GB) | 2012-09-11 | — | — | US | disclosed |
| US-8222266-B2 | Azabicyclo [3.1.0] hexyl derivatives as modulators of dopamine D3 receptors | GLAXO GROUP LIMITED (GB) | 2012-07-17 | — | — | US | disclosed |
| US-8163927-B2 | Azabicyclo [3.1.0] hexane derivatives as modulators of dopamine D3 receptors | GLAXO GROUP LIMITED (GB) | 2012-04-24 | — | — | US | disclosed |
| US-7807698-B2 | Azabicyclo[3.1.0]hexane derivatives as modulators of the dopamine D3 receptor | GLAXO GROUP LIMITED (GB) | 2010-10-05 | — | — | US | disclosed |
| US-20100152195-A1 | Azabicyclo (3.1.0) Hexane Derivatives Useful As Modulators Of Dopamine D3 Receptors | GLAXO GROUP LIMITED | 2010-06-17 | — | — | US | disclosed |
| US-7727988-B2 | Azabicyclo[3.1.0]hex-3-yl}alkyl)pyrimidinedione | GLAXO GROUP LIMITED (GB) | 2010-06-01 | — | — | US | disclosed |
| US-20100069416-A1 | Azabicyclo [3.1.0] Hexyl Derivatives as Modulators of Dopamine D3 Receptors | GLAXO GROUP LIMITED | 2010-03-18 | — | — | US | disclosed |
| US-20100063097-A1 | Azabicyclo [3.1.0] Hexane Derivatives as Modulators of Dopamine D3 Receptors | GLAXO GROUP LIMITED | 2010-03-11 | — | — | US | disclosed |
| US-20080227837-A1 | Novel Compounds | GLAXO GROUP LIMITED (GB) | 2008-09-18 | — | — | US | disclosed |
| US-20070249642-A1 | Azabicyclo[3.1.0]hex-3-yl}alkyl)pyrimidinedione | GLAXO GROUP LIMITED (GB) | 2007-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069416-A1 | Azabicyclo [3.1.0] Hexyl Derivatives as Modulators of Dopamine D3 Receptors | DRD3, DRD2, HTR3A | SLC6A2 512/4885SLC6A4 301/4885SLC6A3 13/4885 |
| US-20100152195-A1 | Azabicyclo (3.1.0) Hexane Derivatives Useful As Modulators Of Dopamine D3 Receptors | DRD3, DRD1, DRD2 | SLC6A2 654/4885SLC6A4 660/4885SLC6A3 26/4885 |
| US-20080227837-A1 | Novel Compounds | HTR5A, NPY5R, DRD3 | SLC6A2 313/4885SLC6A4 137/4885SLC6A3 10/4885 |
| US-20070249642-A1 | Azabicyclo[3.1.0]hex-3-yl}alkyl)pyrimidinedione | AZI2, NT5C3B, CYP1B1 | SLC6A2 2528/4885SLC6A4 2034/4885SLC6A3 1145/4885 |
| US-20100063097-A1 | Azabicyclo [3.1.0] Hexane Derivatives as Modulators of Dopamine D3 Receptors | DRD3, DRD2, DRD1 | SLC6A2 738/4885SLC6A4 493/4885SLC6A3 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.